What You Should Know:
- Pangea Biomed, the biotech company behind ENLIGHT, the multi-cancer response predictor improving the effectiveness of precision oncology, announced $5M in additional funding reaching a total seed round of $12M.
- The latest fundraising is led by angel investor Danny Tocatly and existing investor NFX, and will be used to expand US operations, drive commercial partnerships, and scale product offerings.
Expanding US Operations and Fostering Commercial
Read More
Clinical Trial
Clinical Trials: 5 Steps to Greater eConsent Adoption
Clinical trials advance much-needed treatments while offering hope to patients and their families. However, the process of enrolling in a study where they will receive investigational medicines, vaccines or procedures can be a source of friction – enough for patients to rethink participation.
The weight of the decision combined with a perceived lack of transparency of information can confuse or dismay even those patients that are most savvy in the medical industry. Even if they do end
Read More
Analysis: RSNA 2022: Predictions vs Reality
Much has already been written about attendance at RSNA, but from a first-hand perspective, RSNA 2022 could be regarded as a step back toward “normal”. Amongst mostly bustling halls, vendors reported very positive feedback on the volume and quality of customer meetings, with one prominent global imaging vendor citing “We’re signing deals here at the show again – things are looking up”.
Against this positive backdrop, however, the stark challenges facing radiology in a post-COVID world were
Read More
AI/ML Used for Clinical Trial-Site Identification Simultaneously Improves Enrollment Rates and Diversity
Ethnic and racial minorities are commonly underrepresented in clinical trials. This problem is so severe that in April, the U.S. Food and Drug Administration (FDA) expanded upon existing guidance to further emphasize recommendations to sponsors developing treatments to increase enrollment from underrepresented populations in the U.S., including African-American, Hispanic, Asian and other persons of color, in clinical trials. In the updated guidance, the FDA provided details on what sponsors
Read More
VA Provides Veterans with Immersive, VR Treatment for Chronic Lower Back Pain
What You Should Know:
- AppliedVR, an immersive therapeutics (ITx) pioneer advancing a novel, virtual reality-based approach to medicine, today announced a contract with the U.S. Department of Veterans Affairs (VA) to provide its FDA-authorized RelieVRx (formerly EaseVRx) solution to select Veterans impacted by chronic lower back pain (CLBP).
- AppliedVR was awarded the contract with the VHA Innovation Ecosystem, a division of the VA that discovers, evaluates, and
Read More
Can Doctors Objectively Quantify and Measure Pain?
Millions of Americans live with acute and chronic pain that affects every aspect of their lives. Pain by itself is an important marker of how a patient is feeling and indicates what kind of medical intervention might be necessary. The healthcare industry needs a clinically acceptable way to objectively measure pain and since pain is a very complex mixture of biochemistry and genetics and it’s unlikely that a laboratory test that directly quantifies pain will be developed.
Doctors
Read More
How Virtual-First Clinical Trials Scale Access for Participants
Making clinical trials equitable is one of the biggest challenges we face as an industry. We see this time and again, with one of the latest examples coming in the form of a study published in JAMA Network Open that found substantial underrepresentation of Black patients enrolled in pivotal trials for CAR-T therapy.
Women are another demographic negatively affected by inequality in clinical research. Earlier this month [May 2022] the American Heart Association issued a
Read More
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
What You Should Know:
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors.
- The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
Site Enablement Platforms Can Accelerate Clinical Trials by 6 Weeks and Reduce Costs by Over $1M
What You Should Know:
- Florence HealthcareTM, a clinical research technology company headquartered in Atlanta, Georgia, recently announced the completion of a year-long third-party study on the impact of Site Enablement PlatformsTM on clinical research timelines and costs.
- The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor
Read More
ConcertAI CEO Talks COVID-19 & The De-Risking of Technology to Keep Trials Moving
Nothing like it had ever happened before – a global slowdown in new study starts and a massive decrease in trial accruals for open studies. The turn of events was a shock for sponsors and providers. Sudden disruptions on that scale rarely hit multiple players in an ecosystem at the same time. But that’s exactly what happened at the intersection of clinical care and clinical development during the pandemic. Researchers and clinicians were forced to change how they operated trials, and
Read More
